Last reviewed · How we verify

Diclofenac Sodium gel, 1% — Competitive Intelligence Brief

Diclofenac Sodium gel, 1% (Diclofenac Sodium gel, 1%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Pain Management / Rheumatology.

marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) Pain Management / Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

Diclofenac Sodium gel, 1% (Diclofenac Sodium gel, 1%) — Glenmark Pharmaceuticals Ltd. India. Diclofenac sodium inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain at the site of application.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Diclofenac Sodium gel, 1% TARGET Diclofenac Sodium gel, 1% Glenmark Pharmaceuticals Ltd. India marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
Topical diclofenac sodium gel Topical diclofenac sodium gel Guang'anmen Hospital of China Academy of Chinese Medical Sciences marketed Nonsteroidal anti-inflammatory drug (NSAID) COX-1 and COX-2 enzymes
Ketorolac Nasal Spray Ketorolac Nasal Spray Hersh, Elliot V., DMD, MS, PhD marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1 and COX-2)
aspirin + celecoxib aspirin + celecoxib Seoul National University Hospital marketed Nonsteroidal anti-inflammatory drug (NSAID) combination COX-1 and COX-2 enzymes
Nerkardou (5 mg) & (10 mg) Nerkardou (5 mg) & (10 mg) Genuine Research Center, Egypt marketed Nonsteroidal anti-inflammatory drug (NSAID) COX-2
Bromfenac Sodium 0.07% Bromfenac Sodium 0.07% Retina Research Institute, LLC marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1 and COX-2)
Pranoprofen Eyedrops Pranoprofen Eyedrops Università degli Studi di Brescia marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1, COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

  1. Università degli Studi di Brescia · 4 drugs in this class
  2. Bausch & Lomb Incorporated · 4 drugs in this class
  3. Bayer · 3 drugs in this class
  4. Pfizer · 3 drugs in this class
  5. Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
  6. Organon and Co · 3 drugs in this class
  7. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
  8. Bezmialem Vakif University · 2 drugs in this class
  9. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
  10. Center For Excellence In Eye Care · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Diclofenac Sodium gel, 1% — Competitive Intelligence Brief. https://druglandscape.com/ci/diclofenac-sodium-gel-1. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: